<DOC>
	<DOCNO>NCT00199030</DOCNO>
	<brief_summary>This study test effectivity tolerability treatment alemtuzumab ( MabCampath ) patient relapsed refractory T-cell acute lymphoblastic leukemia ( T-ALL ) T-lymphoblastic lymphoma . In Arm A , patient refractory relapse receive 2 week treatment MabCampath follow remission evaluation . In case insufficient response , treatment cladribine add . In Arm B , patient molecular relapse ( minimal residual disease ) receive 4 week treatment MabCampath follow remission evaluation . In arm , treatment continue case response two month .</brief_summary>
	<brief_title>Treatment Relapsed T-Cell Acute Lymphoblastic Leukemia T-Lymphoblastic Lymphoma With MabCampath</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Both Arms : TALL Tlymphoblastic lymphoma CD52expression &gt; 20 % Aged &gt; = 18 year ECOG/World Health Organization ( WHO ) performance status 02 Life expectancy &gt; 2 month Contraception , least 6 month , therapy At least 2 week interval last cycle chemotherapy ( decision individual case rapid progression ) No persistent toxicity earlier cycle Written inform consent Arm 1 : Evidence MRD &gt; 10 ( 4 ) confirmation beyond week 16 GMALLStudy 07/2003 Arm 2 : Relapse failure least one salvage therapy primary failure induction therapy least one salvage therapy Substantial restriction heart , lung , liver , kidney function Active infection , HIV seropositivity cytomegalovirus ( CMV ) viraemia Pretreatment MabCampathÂ® Known anaphylaxis humanise antibody Permanent systemic therapy corticosteroid Central nervous system ( CNS ) involvement Extramedullary bulky disease Active secondary malignancy Pregnancy nursing Mental disease circumstance prohibit compliance protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Relapse</keyword>
	<keyword>T-ALL</keyword>
	<keyword>T-LBL</keyword>
	<keyword>MabCampath</keyword>
	<keyword>Minimal residual disease</keyword>
	<keyword>Lymphoma , lymphoblastic , T-cell</keyword>
</DOC>